Live
FierceBiotechJapan, South Korea challenge the West’s place in research rankings: reportEndpoints NewsCMS seeks to close Medicare negotiation 'loophole'Endpoints NewsFDA plans to keep Makary priorities on trials, China, deputy saysClinical OMICsTwo Women, One Mission: Closing the Gap Between Cancer Science and SurvivalEndpoints NewsTakeda fortifies orexin potential with more Phase 3 dataEndpoints NewsElicio’s KRAS cancer vaccine fails in Phase 2, shares plummetFierceBiotechAmid US investment tour, J&J makes $1B stop in Florida to upgrade contact lens plantEndpoints NewsGan & Lee's Phase 3 obesity successes; J&J touts multiple myeloma dataFierceBiotechAmgen loses in Harbour antibody patent case, ordered to pay $20M+FierceBiotechIntellia touts ‘paradigm-shifting’ phase 3 data for one-time HAE treatmentBioWorldElicio phase II results in pancreatic cancer wreck sharesBioWorldBiggest gainers and losers for June 8-12, 2026
Endpoints News May 1, 2026

Summit slips on ivonescimab's apparent interim miss in sign of investor frustration

Summit slips on ivonescimab's apparent interim miss in sign of investor frustration

Body unavailable. Use the original source.